Lantheus Alpha Therapy, LLC - 03 Sep 2026 Form 4 Insider Report for Perspective Therapeutics, Inc. (CATX)

Reporting relationship: 10%+ Owner
Issuer ticker: CATX
Reported as of: 03 Sep 2026
Net transaction value: -$776,947
SEC form: 4
Accepted by SEC: 08 Sep 2026, 16:51:19 UTC
Prior SEC filing: 04 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Eric M. Green, Assistant Corporate Secretary of Lantheus Holdings

Key filing fact

Lantheus Alpha Therapy, LLC filed Form 4 for Perspective Therapeutics, Inc. (CATX) on 08 Sep 2026.

Key facts

This page summarizes Lantheus Alpha Therapy, LLC's Form 4 filing for Perspective Therapeutics, Inc. (CATX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Sep 2026, 16:51.

Change

Previous filing in this sequence was filed on 04 Sep 2026.
Current net transaction value: -$776,947.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002010224 Primary reporting owner

Lantheus Alpha Therapy, LLC

Relationship: 10%+ Owner
Address: C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD
Signature: /s/ Eric M. Green, Assistant Corporate Secretary of Lantheus Holdings
Signature date: 08 Sep 2026

CIK 0001521036

Lantheus Holdings, Inc.

Relationship: 10%+ Owner
Address: 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD
Signature: /s/ Eric M. Green, Assistant Corporate Secretary of Lantheus
Signature date: 08 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CATX transaction

Common Stock

Sale

Transaction value: $250,896
Shares: -80,783
Change %: -0.7%
Price: $3.11
Shares after: 11,440,513
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1, F2

CATX transaction

Common Stock

Sale

Transaction value: $250,896
Shares: -80,783
Change %: -0.7%
Price: $3.11
Shares after: 11,440,513
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1, F2

CATX transaction

Common Stock

Sale

Transaction value: $526,051
Shares: -167,149
Change %: -1.5%
Price: $3.15
Shares after: 11,273,364
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F2, F3

CATX transaction

Common Stock

Sale

Transaction value: $526,051
Shares: -167,149
Change %: -1.5%
Price: $3.15
Shares after: 11,273,364
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Lantheus Alpha Therapy, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Footnote F2

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.